AVHEC 2019
AVHEC 2019


ExhibitorCompany Profile
AbbVie is a highly focused, research-driven biopharmaceutical company. We’re a company that takes on some of the toughest health challenges. And we do more than just treat diseases – we aim to make a remarkable impact on people’s lives.
Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.
Gilead’s mission is to advance patient care by developing therapeutics to treat life-threatening diseases. We apply biopharmaceutical science to create medicines to treat conditions including Haematology/Oncology (ZYDELIG® [idelalisib]), HIV (BIKTARVY® [bictegravir/emtricitabine/tenofovir alafenamide] DESCOVY® [emtricitabine/tenofovir alafenamide], GENVOYA® [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide], STRIBILD® [tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat], EVIPLERA® [tenofovir disoproxil fumarate/emtricitabine/rilpivirine], ATRIPLA® [tenofovir disoproxil fumarate/ emtricitabine/efavirenz], TRUVADA® [emtricitabine/tenofovir disoproxil fumarate], EMTRIVA® [emtricitabine], VIREAD® [tenofovir disoproxil fumarate]), chronic hepatitis B (VIREAD® [tenofovir disoproxil fumarate], HEPSERA® [adefovir dipivoxil]), chronic hepatitis C (EPCLUSA® [sofosbovir/velpatasvir], HARVONI® [ledipasvir/sofosbovir], SOVALDI® [sofosbuvir], VOSEVI® [sofosbuvir/velpatasvir/voxilaprevir]), and systemic fungal infections (AmBisome® [liposomal amphotericin B])
Hepatitis Australia and Hepatitis NSW form part of the national network of community hepatitis organisations. We work both together and independently to improve the health and wellbeing of people living with viral hepatitis. Hepatitis Australia is the peak community organisation to progress national action on hepatitis B and hepatitis C. Hepatitis NSW is a state-based organisation, and a member organisation of Hepatitis Australia. It provides information, support, referral, advocacy and community engagement/representation for people affected by viral hepatitis. Through collaboration and partnership at all levels, we believe that the quest to eliminate viral hepatitis as a public health concern by 2030 is achievable, but we need to work together!
The beauty of the Fibroscan is that the basic principle of measurement has not changed, however, the new transportable model FS430 is much smaller recent hardware and software make accuracy easier and faster by eliminating A and E waves. At some time in the next 6 to 9 months there will be dual probe depth software to reduce capsule errors and CAP will measure steatosis in a potentially larger area, we expect that this will only be available on new devices such as the FS 430-Step2 just released.